Erythropoietin receptor is detectable on peripheral blood lymphocytes and its expression increases in activated T lymphocytes.

We are writing to comment on the article by Lifshitz L et al. published in Haematologica in June 2010: “Macrophages as novel target cells for erythropoietin”. We read the article with great interest but we have to stress that the Authors have passed over our publications concerning immunomodulatory action of recombinant human erythropoietin (rhEPO) from over the last 12 years. Thus, based on our own observations which were published before the Lifshitz paper, we have to challenge their claims that “....EPO-receptors were not detectable in lymphocytes...” (Introduction, p. 1,824 supported by citation of Prutchi-Sagiv et al.) and “however, EPO-receptor expression or direct EPO stimulation on lymphocytes could not be demonstrated to date”. Recombinant human erythropoietin is commonly used for treatment of anemia related to chronic renal failure (CRF). Receptor for erythropoietin (EPO-R) has been found in other tissues and cells apart from erythroid cells, including neurons, endothelial cells, some solid tumor cells and various types of renal cells, but also polymorphonuclear leukocytes. Both EPO-R structure and its presence on leukocytes indicated that beyond erythropoietic function, EPO might possess some immunomodulatory properties. Patients who have undergone hemodialysis (HD) exhibit deficiency in both cell mediated and humoral immunity and that is why they presented good material for studies concerning rhEPO. We have demonstrated a direct influence of rhEPO treatment on secretion of cytokines (IL-2, IL-10 and TNF-a) for the first time in 1998 and on activation parameters of CD4 T lymphocytes in HD patients with chronic renal failure (CRF). We found that addition of rhEPO in vitro to the whole blood cell cultures of the HD patients before implementation of rhEPO directly stimulates IL-2 production. Also rhEPO therapy itself affected IL-2 production. In the meantime, level of IL-10 increased in all rhEPO-treated patients during the therapy, while level of TNF-a was temporarily decreased. RhEPO treatment normalized the decreased expression of CD28 and CD69 on CD4 lymphocytes of HD patients. We have also studied the kinetics of proliferation of CD4 T lymphocytes by DCT cytometric technique and we found that fewer CD4CD28 T cells of patients not receiving rhEPO proliferated after stimulation; these cells needed longer to enter the first division cycle. Moreover, this year we have also published an article that for the first time describes presence of erythropoietin receptor (EPO-R) on human blood lymphocyte and monocyte surface using quantitative flow cytometry to calculate the exact numbers of these receptors. The notion of EPO-R being expressed by human lymphocytes was supported by our finding of EPO-R mRNA in peripheral blood mononuclear cells as well as in isolated CD4 T lymphocytes. The results suggested that rhEPO action on those cells can be direct. To verify this hypothesis, we have stimulated peripheral blood mononuclear cells (PBMC) with immobilized anti-CD3 antibody (250 ng per 2 million cells in 2 mL of complete medium) and incubated for five days at 37°C, 5% CO2. Stimulated cells were collected after 48, 72 and 120 h and stained with PE-conjugated anti-EpoR monoclonal antibody and RPE-Cy5-conjugated anti-CD4 for 30 min at 4°C. After washing twice in PBS, cells were resuspended in 200 μL of the same buffer for flow cytometric analysis performed directly after sample preparation. Quantitative fluorescence analysis assessing the numbers of EPO-R bound per cell was performed using Phycoerythrin Fluorescence Quantitation Kit (Becton Dickinson, USA) according to the manufacturer’s protocol, and a FACScan flow cytometer (Becton Dickinson, USA). Stimulation of PBMC in vitro resulted in increased EPO-R molecule number on CD4 lymphocytes after 48